|
Administration
May be taken with or without food.
|
|
Contraindications
Phaeochromocytoma, history of neuroleptic malignant syndrome and/or non-traumatic rhabdomyolysis. Hepatic impairment. Concomitant use w/ non-selective MAOIs.
|
|
Special Precautions
Patient w/ biliary obstruction, ischaemic heart disease. Avoid abrupt withdrawal. Pregnancy and lactation. Patient Counselling This drug may cause reddish-brown discolouration of urine. When given w/ levodopa, may cause dizziness and symptomatic orthostatism, if affected, do not drive or operate machinery. Monitoring Parameters Monitor BP, hepatic function, mental status and impulse control disorders, daytime sleepiness, serum Fe, wt loss; signs/symptoms of Parkinson's disease, neuroleptic malignant syndrome (if abrupt withdrawal is required); regular dermatologic examination.
|
|
Adverse Reactions
Abdominal pain, nausea, vomiting, diarrhoea, constipation, colitis, dry mouth, dyskinesia, dizziness, nightmares, insomnia, hallucinations, confusion, fatigue, increased sweating, behavioural disturbances; urine, skin, hair, beard and nail discolourations; cholestatic hepatitis, rhabdomyolysis. Rarely, agitation, urticaria, erythematous or maculopapular rash, anorexia, wt decrease, increased liver enzymes.
Potentially Fatal: Neuroleptic malignant syndrome (NMS)-like syndrome (w/ abrupt reduction or withdrawal). |
|
Drug Interactions
May interfere w/ metabolism of other drugs metabolised by COMT (e.g. rimiterole). May aggravate levodopa-induced orthostatic hypotension. Risk of dopaminergic effects w/ dopamine agonists (e.g. bromocriptine), selegiline, amantadine. May form chelates w/ Fe in the GI tract. Additive sedative effects w/ other CNS depressants.
|
|
CIMS Class
|
|
ATC Classification
N04BX02 - entacapone ; Belongs to the class of other dopaminergic agents used in the management of Parkinson's disease.
|
Sign Out
